Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Kidney Injury. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Utility of Cystatin C in the Early Detection of Contrast Induced Acute Kidney Injury
Overview
To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).
Detailed description
The primary objective of this study is to evaluate the clinical utility of Cystatin C in early detection of contrast-induced AKI.
To evaluate the effect of patient characteristics in the Cystatin C based GFR estimation in comparison to Cr based estimation.
Primary outcome measures
- Incidence of AKI when sCr is used compared to when sCyC is used 24-48 hours after contract media and at 7-10 days follow-up [Time frame: 10 days]
Secondary outcome measures (1)
- Change from baseline in eGFRcr compared to change from baseline in eGFRcys 24-48 hours after contrast media and at 7 to 10 days follow-up [Time frame: 10 days]
Eligibility criteria
Inclusion criteria
- Subjects ages 18 years and above
- Inpatients with CKD (Figure 1)
- Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media.
- Pre and post contrast available
- All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.
Exclusion criteria
- Preexisting dialysis
- Patients under the age of 18 years
- Pregnancy
- Incarcerated individuals
- Patients with impaired cognition and unable to follow consent procedures
- Recent exposure to CM (within 2 days before/after procedure)
- Cardiac shock
- Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 4 centers
- Morton Plant Hospital — Clearwater
- Morton Plant North Bay Hospital — New Port Richey
- Mease Countryside Hospital — Safety Harbor
- St. Anthony's Hospital — St. Petersburg
Identifiers
NCT: NCT07197957 · Cystatin & Early AKI Detection